<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cipla Ltd — News on 6ix</title>
<link>https://6ix.com/company/cipla-limited</link>
<description>Latest news and press releases for Cipla Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 13:04:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cipla-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683648b278dffbe2df1523a2.webp</url>
<title>Cipla Ltd</title>
<link>https://6ix.com/company/cipla-limited</link>
</image>
<item>
<title>Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA</title>
<link>https://6ix.com/company/cipla-limited/news/cipla-receives-us-fda-approval-for-first-ab-rated-generic-of-ventolinr-hfa</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/cipla-receives-us-fda-approval-for-first-ab-rated-generic-of-ventolinr-hfa</guid>
<pubDate>Thu, 23 Apr 2026 13:04:00 GMT</pubDate>
<description>Cipla Limited (BSE: 500087) (NSE: CIPLA-EQ) (hereafter referred to as 'Cipla') and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as 'Cipla'), today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation from the United States Food and Drug Administration (USFDA). It is the first AB–rated generic therapeutic equivalent of Ventolin® HFA, marketed by GlaxoSmithKline.</description>
</item>
<item>
<title>Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis</title>
<link>https://6ix.com/company/cipla-limited/news/cipla-expands-us-respiratory-portfolio-with-approval-of-nintedanib-capsules-100mg-and-150mg-for-idiopathic-pulmonary-fibrosis</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/cipla-expands-us-respiratory-portfolio-with-approval-of-nintedanib-capsules-100mg-and-150mg-for-idiopathic-pulmonary-fibrosis</guid>
<pubDate>Fri, 03 Apr 2026 03:11:00 GMT</pubDate>
<description>Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087) (NSE: CIPLA) (hereafter referred to as "Cipla") today announced final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, 100 mg and 150 mg, indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF).</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation</title>
<link>https://6ix.com/company/cipla-limited/news/fennec-pharmaceuticals-announces-settlement-agreement-resolving-pedmark-patent-litigation-1</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/fennec-pharmaceuticals-announces-settlement-agreement-resolving-pedmark-patent-litigation-1</guid>
<pubDate>Mon, 16 Mar 2026 12:08:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them regarding Cipla’s application to FDA for approval to market a generic version of Fennec’s PEDMARK® (sodium thiosulfate injection) product. See Fennec Pharmaceuticals Inc. v. Cipla Limited and Cipla USA, Inc., C.A. N</description>
</item>
<item>
<title>Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy</title>
<link>https://6ix.com/company/cipla-limited/news/cipla-strengthens-us-portfolio-with-the-launch-of-generic-saxendar-liraglutide-injection-for-weight-management-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/cipla-strengthens-us-portfolio-with-the-launch-of-generic-saxendar-liraglutide-injection-for-weight-management-therapy</guid>
<pubDate>Fri, 27 Feb 2026 16:28:00 GMT</pubDate>
<description>Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single–patient–use prefilled pens, the generic equivalent of Saxenda® (liraglutide injection).</description>
</item>
<item>
<title>Press Release Jan 23 2026</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-jan-23-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-jan-23-2026-2</guid>
<pubDate>Fri, 23 Jan 2026 18:41:12 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated January 23, 2026, titled "Q3 FY26 Results".</description>
</item>
<item>
<title>Cipla USA Strengthens Lung Leadership with Community Wellness Initiatives</title>
<link>https://6ix.com/company/cipla-limited/news/cipla-usa-strengthens-lung-leadership-with-community-wellness-initiatives</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/cipla-usa-strengthens-lung-leadership-with-community-wellness-initiatives</guid>
<pubDate>Mon, 17 Nov 2025 13:30:00 GMT</pubDate>
<description>Reinforcing its mission of helping millions breathe free and foster healthier communities, Cipla USA Inc. (Cipla USA) announced its continued commitment with the COPD Foundation for the third consecutive year. Chronic Obstructive Pulmonary Disease (COPD) impacts the lives of about 30 million Americans1 who suffer from the disease. Against this backdrop, Cipla USA seeks to drive innovation and enhance access for COPD patients through its respiratory care leadership.</description>
</item>
<item>
<title>Press Release Oct 30 2025</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-oct-30-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-oct-30-2025-2</guid>
<pubDate>Thu, 30 Oct 2025 17:54:03 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated October 30, 2025, titled "Q2 FY26 Results".</description>
</item>
<item>
<title>Cipla Expands Fall River Operations in USA, Announces Upcoming Hiring for Various Roles</title>
<link>https://6ix.com/company/cipla-limited/news/cipla-expands-fall-river-operations-in-usa-announces-upcoming-hiring-for-various-roles</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/cipla-expands-fall-river-operations-in-usa-announces-upcoming-hiring-for-various-roles</guid>
<pubDate>Thu, 07 Aug 2025 13:00:00 GMT</pubDate>
<description>Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla" today announced a significant expansion of its manufacturing facility located at Innovation Way in Fall River, Massachusetts. This expansion includes an 83,000-square-foot addition to the existing facility, aimed at increasing production capacity and enhancing operational efficiency. Cipla is expanding its US manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced</description>
</item>
<item>
<title>Press Release Jul 25 2025</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-jul-25-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-jul-25-2025-1</guid>
<pubDate>Fri, 25 Jul 2025 17:32:32 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated July 25, 2025, titled "Press Release".</description>
</item>
<item>
<title>Press Release May 13 2025</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-may-13-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-may-13-2025-2</guid>
<pubDate>Tue, 13 May 2025 18:21:59 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated May 13, 2025, titled "Press release ".</description>
</item>
<item>
<title>Press Release Jan 28 2025</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-jan-28-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-jan-28-2025-1</guid>
<pubDate>Tue, 28 Jan 2025 19:16:14 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated January 28, 2025, titled "Press Release Q3FY25".</description>
</item>
<item>
<title>Press Release Oct 29 2024</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-oct-29-2024-2</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-oct-29-2024-2</guid>
<pubDate>Tue, 29 Oct 2024 18:22:59 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated October 29, 2024, titled "Q2 FY25 results".</description>
</item>
<item>
<title>Press Release Jul 26 2024</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-jul-26-2024-3</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-jul-26-2024-3</guid>
<pubDate>Fri, 26 Jul 2024 19:08:19 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated July 26, 2024, titled "Q1 FY25 results".</description>
</item>
<item>
<title>Press Release Jun 18 2024</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-jun-18-2024-1</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-jun-18-2024-1</guid>
<pubDate>Tue, 18 Jun 2024 18:41:55 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated Jun 18, 2024, titled "Press Release - Cipla EU to invest an additional EUR 3 million in Ethris".</description>
</item>
<item>
<title>Press Release May 10 2024</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-may-10-2024</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-may-10-2024</guid>
<pubDate>Fri, 10 May 2024 18:42:22 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated May 10, 2024, titled "Q4 & FY24 results".</description>
</item>
<item>
<title>Press Release Mar 26 2024</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-mar-26-2024</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-mar-26-2024</guid>
<pubDate>Tue, 26 Mar 2024 23:49:41 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated March 26, 2024, titled "Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in India".</description>
</item>
<item>
<title>Press Release Jan 22 2024</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-jan-22-2024-1</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-jan-22-2024-1</guid>
<pubDate>Tue, 23 Jan 2024 00:22:09 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated January 22, 2024, titled "Cipla Q3 FY24 Press Release".</description>
</item>
<item>
<title>Press Release Jan 08 2024</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-jan-08-2024</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-jan-08-2024</guid>
<pubDate>Mon, 08 Jan 2024 22:39:55 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated January 08, 2024, titled "Cipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group for global development and commercialisation of innovative Cell therapy products ".</description>
</item>
<item>
<title>Press Release (Revised) Dec 15 2023</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-revised-dec-15-2023</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-revised-dec-15-2023</guid>
<pubDate>Sat, 16 Dec 2023 04:45:55 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a revised press release dated December 15, 2023, titled "Revised Press Release - This is further to the press release submitted by the Company on 10th December 2023. It was brought to our attention by US FDA that there was information in our risk assessment that was not pertinent to this product. As a result we are reissuing a revised press release on the said matter.</description>
</item>
<item>
<title>Press Release Dec 14 2023</title>
<link>https://6ix.com/company/cipla-limited/news/press-release-dec-14-2023-1</link>
<guid isPermaLink="true">https://6ix.com/company/cipla-limited/news/press-release-dec-14-2023-1</guid>
<pubDate>Fri, 15 Dec 2023 03:27:35 GMT</pubDate>
<description>Cipla Limited has informed the Exchange regarding a press release dated December 14, 2023, titled "Acquisition of additional stake in GoApptiv Private Limited".</description>
</item>
</channel>
</rss>